Strides has agreed to partner with Orbicular to develop four nasal sprays targeting a combined market worth more than $400m for markets including Europe and the US.
Strides Pharma Science has struck a deal with fellow Indian firm Orbicular Pharmaceutical Technologies Private Limited to develop, manufacture and sell four nasal sprays for global markets. Citing IQVIA data, Strides said the four undisclosed nasal sprays had a combined market size “in excess of $400m.”
The strategic partnership will see the pair “leverage Orbicular’s advanced development capabilities with Strides’ US Food and Drug Administration approved...
Melinta Therapeutics has prevailed at the Federal Circuit in a patent dispute over its reformulated intravenous antibiotic Minocin, with the appeals court upholding both infringement and validity and leaving Nexus Pharmaceuticals barred from launching a generic until 2031.
Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains
